Filters
This advisory introduces readers to digital therapeutics (DTx) and the benefits of their use in behavioral health. It describes the research, regulatory, and reimbursement implications for DTx as well as selection and implementation considerations.
View ResourceThis Advisory outlines how healthcare providers (i.e., obstetrician-gynecologists [OB-GYNs], primary care physicians, and other professionals who treat pregnant people) can take an active role in supporting the health of pregnant individuals who have OUD and their babies.
View ResourceThis advisory introduces readers to cannabidiol (CBD), how it is derived, and how it differs from delta-9 THC and other cannabinoids. The advisory focuses on the risks and harms of CBD, especially those sold over the counter. This advisory also clarifies common misconceptions about CBD, given its broad availability and marketing for several medical conditions despite limited evidence of efficacy.
View ResourceThis guide focuses on research supporting adaptations of evidence-based practices (EBPs) for under-resourced populations. Adaptations involve tailoring care, programs, and services to the cultural, social, gender, and demographic contexts of the people served to yield positive outcomes.
View ResourceThe ASAM Clinical Practice Guideline on Alcohol Withdrawal Management is intended to aid clinicians in their clinical decision-making and management of patients experiencing alcohol withdrawal syndrome.
View ResourceThis guide developed by the American Society of Addiction Medicine (ASAM) provides healthcare providers with instant access to current guidelines in a clear concise format.
Chronic pain is common, multidimensional, and individualized, and treatment can be challenging for healthcare providers as well as patients. In response to the critical need for consistent and current opioid prescribing guidelines, the CDC released the Guideline for Prescribing Opioids for Chronic Pain.
View ResourceThis pocket guide was produced by the American Society of Addiction Medicine (ASAM) and the National Association of Drug Court Professionals (NADCP) guide.
View ResourceThis advisory summarizes data on the use of sublingual and transmucosal buprenorphine as part of medication-assisted treatment (MAT) for opioid use disorder.
View Resource